IMPACT OF PSYCHIATRIC MEDICINE, PHARMACOTHERAPY, AND DRUG METABOLISM ON DEPRESSION AND EMOTIONAL REGULATION IN ADOLESCENTS

Abstract

Background: Adolescence is this kind of dynamic neurodevelopmental phase, where neural circuits in charge of emotion control, reward processing, executive regulation, stress responsivity and social cognition start maturing a lot. During this time, depression often shows up together with emotional dysregulation, sleep problems , harder thinking, and reduced psychosocial functioning. This review sort of brings together psychological, neurobiological, psychiatric, pharmacological and pharmaco-metabolic lenses, to look at how adolescent depression links to emotional regulation, and there’s a special focus on antidepressant pharmacotherapy plus cytochrome P450 mediated drug metabolism. Method: This kind of qualitative narrative review goes through current literature that talks about adolescent depression and emotional regulation, neurodevelopment and the prefrontal limbic circuitry, reward processing and also hypothalamic-pituitary-adrenal-axis activity. It also touches inflammation, neuroplasticity, sleep, and then moves into antidepressant pharmacotherapy, including pharmacokinetics, pharmacodynamics , and pharmacogenetics. There is, in a way, special attention on CYP2C19 and CYP2D6 , since they’re already known to be tied in with the metabolism of several antidepressants. Adolescent depression seems to come about from a messy set of interactions between developmental, psychological, environmental, and biological processes, not like one lone neurochemical glitch. Result & Conclusion: Emotional regulation might be a key clinical phenotype, sort of linking altered affective processing, with the later depressive symptoms too. At the same time, antidepressant exposure isn’t consistent across individuals, and variation in CYP2C19 and CYP2D6 genetics could help explain differences in pharmacokinetics, and tolerability. But, the developmental stage, co-prescribed drugs, how well someone sticks to the regimen, the disease characteristics and the surrounding environment, all steer the treatment response. So, integrating emotional regulation and neurobiology with pharmacokinetics and pharmacogenetics might end up giving this more complete framework for figuring out why people respond differently. Still, the evidence in pediatrics is kind of less developed compared with adults, and genotype shouldn’t be read as a self-standing cause of antidepressant efficacy.